Targeting plasma cells that produce harmful antibodies for organ transplantation
Proteasome targeting for alloreactive plasma cells
This study is looking at how to get rid of certain cells in the body that make antibodies against transplanted organs, which can cause problems for people who have received a transplant, and it’s testing a special treatment to see how well it works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10877179 on NIH RePORTER |
What this research studies
This research investigates how to effectively eliminate long-lived plasma cells that produce antibodies against transplanted tissues, which is a significant challenge in organ transplantation. The approach focuses on using proteasome inhibitors to deplete these plasma cells, while also examining how newly formed plasma cells respond to these treatments. By understanding the differences in response between long-lived and newly formed plasma cells, the research aims to improve strategies for managing antibody production that can hinder successful transplants.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals undergoing organ transplantation who may be at risk of developing antibodies against donor tissues.
Not a fit: Patients who are not undergoing transplantation or do not have issues related to antibody production may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved transplant outcomes by reducing harmful antibody production in patients.
How similar studies have performed: Previous research has shown promise in using proteasome inhibitors for similar applications, indicating potential for success in this approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Allman, David M — University of Pennsylvania
- Study coordinator: Allman, David M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.